Candida auris: A Global Emerging Multidrug Resistant Pathogen (CE Session)

4.96 (24 votes)


Date/Time: April 11, 2024 | 2:40 - 3:15 pm ET

Candida auris has swiftly emerged as a global health concern, presenting unique challenges in healthcare settings worldwide. This session delves into the intricate landscape of this multidrug-resistant fungal pathogen, highlighting its epidemiology, clinical implications, and management strategies. From infection control measures to treatment modalities, the complexities associated with managing this emerging fungal pathogen in diverse healthcare settings will be explored. Attendees will gain insights into the molecular mechanisms underpinning its ability to evade host defenses and establish persistent infections, enhancing understanding of its clinical impact.

Learning Objectives:

At the end of the session, the learner should be able to:

  • Identify the challenges associated with caring for patients colonized by Candida auris as an emerging fungal pathogen;
  • List the virulence factors of Candida auris.

Target Audience: 

Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.

Mahmoud A. Ghannoum, PhD, MBA, FIDSA, FAAM


Case Western Reserve University and University Hospitals Cleveland Medical Center

Mahmoud A. Ghannoum, PhD, MBA, FIDSA, FAAM, is a distinguished professor at Case Western Reserve University and University Hospitals Cleveland Medical Center, where he also serves as Director of the Integrated Microbiome Core and Center for Medical Mycology. Dr. Ghannoum has an extensive academic background, including an MSc in Medicinal Chemistry and a PhD in Microbial Physiology from the University of Technology in Loughborough, England, and an MBA from the Weatherhead School of Management at Case Western Reserve University, Cleveland, OH.

Dr. Ghannoum is a leading authority in microbiology and entrepreneurship. He has authored over 450 peer-reviewed publications and six scientific books, placing him in the top 1% of cited scientists worldwide. Dr. Ghannoum is renowned for his pioneering work on fungal communities, coining the term "Mycobiome," and establishing a multidisciplinary Center of Excellence bridging basic and translational research. Recognized for his outstanding contributions, he has been honored with prestigious awards such as the Rhoda Benham Award from the Medical Mycological Society of the Americas (MMSA) and the Freedom to Discover Award from Bristol-Myers Squibb. Dr. Ghannoum is a Fellow of the Infectious Disease Society of America (IDSA), past President of MMSA, and a Fellow of the American Academy of Microbiology (FAAM) and the European Society of Clinical Microbiology and Infectious Diseases (FESCMID). Additionally, he is an entrepreneur-scientist, founding several companies focused on biofilm infections and microbial dysbiosis treatments.

Components visible upon registration.